Insmed (INSM) reported a first quarter net loss of $163.6 million, or $0.76 per share, compared to a net loss of $256.6 million, or $1.42 per share, a year ago. Product revenues, net, was $305.96 million compared to $92.82 million.
The company reiterated 2026 BRINSUPRI revenue guidance of at Least $1 billion and 2026 ARIKAYCE revenue guidance of $450 million to $470 million.
As of March 31, 2026, Insmed had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion.
In pre-market trading on NasdaqGS, Insmed shares are down 5.15 percent to $130.04.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.